Surgical Deactivation of Headache Trigger Sites

This policy addresses surgical deactivation of headache trigger sites (frontal, temporal, rhinogenic, occipital) as a proposed treatment for migraine and select non‑migraine headaches attributed to irritation of trigeminal or occipital nerve branches. The procedure is considered experimental/investigational and unproven, is not FDA‑regulated, and when considered requires identification of trigger sites by clinical evaluation with diagnostic botulinum toxin A injections demonstrating ≥50% symptom reduction (up to three injections) before surgical candidacy.

"Migraine headache is a recurrent disorder with attacks typically lasting 4 to 72 hours."

Sign up to see full coverage criteria, indications, and limitations.